Alumis Inc. ALMS
Alumis Inc. (Nasdaq: ALMS) is an immunology/inflammation drug developer. Its lead program, envudeucitinib (envu, formerly ESK-001), is in Phase 3 for moderate-to-severe plaque psoriasis. Its next catalyst on record is A-005: Initiate Phase 2 biomarker trial in Parkinson's disease (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: A-005 — Initiate Phase 2 biomarker trial in Parkinson's disease (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| envudeucitinib (envu) | plaque psoriasis (pivotal Phase 3 ONWARD1/ONWARD2 complete; ONWARD3 LTE ongoing) | small molecule | Phase 3 |
| envudeucitinib (envu) | systemic lupus erythematosus | small molecule | Phase 2 |
| A-005 | CNS / neuroinflammatory disease (Parkinson's disease biomarker trial planned) | small molecule | Phase 1 |
| lonigutamab | thyroid eye disease | antibody | Phase 1 |
Recent results and decisions
- Sep 1, 2026missed Phase 2b LUMUS did not meet its primary (BICLA Week 48) or secondary endpoints in the overall population (n=408); responses seen in prespecified IFNGS-high subgroup.
LUMUS trial did not meet its primary and secondary endpoints in the overall trial population
Filing - Aug 10, 2026positive ONWARD3 long-term extension: after up to 48 weeks of continuous treatment 75% reached PASI 90 and 54% PASI 100 (n=773), with no new safety signals.
75% and 54% of patients achieved PASI 90 and PASI 100, respectively
Filing - Jan 6, 2026met Phase 3 ONWARD1 met co-primary endpoints PASI 75 and sPGA 0/1 at Week 16 vs placebo (p<0.0001); pooled avg 74% PASI 75, 59% sPGA 0/1; ~65% PASI 90 and >40% PASI 100 at Week 24.
Envudeucitinib met all primary and secondary endpoints with high statistical significance in ONWARD1 and ONWARD2.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
- Sanofi SNY
- Argenx SE ARGX
- Roivant Sciences Ltd. ROIV
- Immunovant, Inc. IMVT
- Celldex Therapeutics, Inc. CLDX
- Biohaven Ltd. BHVN
- BioCryst Pharmaceuticals, Inc. BCRX
- Zenas BioPharma ZBIO
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.